☆ 4.7 Meeting Abstract

FIRST PHASE 2 RESULTS OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL; LN-145) MONOTHERAPY IN PATIENTS WITH ADVANCED, IMMUNE CHECKPOINT INHIBITOR-TREATED, NON-SMALL CELL LUNG CANCER (NSCLC)

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Get Full Text
Add to Collection

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 9, Issue -, Pages A486-A487

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-SITC2021.458

Keywords

-

Categories

Oncology Immunology

Funding

  1. Iovance Biotherapeutics, Inc. (San Carlos, CA, USA)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.